Physician profile
Martin Gordon
NPI 1447353313
$8,973.41
in general payments reported to CMS, 2019-2025
40 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,753 · 2020: $1,255 · 2021: $1,146 · 2022: $1,344 · 2023: $1,096 · 2024: $1,367 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,001.31 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $850.22 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $781.73 | 2019-2025 | Tezspire, Otezla, Repatha |
| Mallinckrodt Hospital Products INC. | $721.44 | 2020-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.83 | 2019-2024 | Ofev |
| Merck Sharp & Dohme LLC | $337.95 | 2019-2025 | Pifeltro, Capvaxive |
| Mylan Specialty L.P. | $330.71 | 2019-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $325.39 | 2023-2025 | Purified Cortrophin Gel |
| Abbvie INC. | $300.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $299.93 | 2020-2025 | |
| Insmed, INC. | $266.00 | 2024-2025 | Arikayce, Brinsupri |
| Advanced Respiratory, INC | $256.38 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.80 | 2024 | Xifaxan |
| Mallinckrodt Enterprises LLC | $221.86 | 2019 | |
| Idorsia Pharmaceuticals US INC | $203.52 | 2023-2025 | Quviviq, Quviviq |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.